Hepatic Metastasis from Colorectal Cancer
- PMID: 29201802
- PMCID: PMC5670263
- DOI: 10.5005/jp-journals-10018-1241
Hepatic Metastasis from Colorectal Cancer
Abstract
The liver is the most common site of metastasis in patients with colorectal cancer due to its anatomical situation regarding its portal circulation. About 14 to 18% of patients with colorectal cancer present metastasis at the first medical consultation, and 10 to 25% at the time of the resection of the primary colorectal cancer. The incidence is higher (35%) when a computed tomography (CT) scan is used. In the last decades, a significant increase in the life expectancy of patients with colorectal cancer has been achieved with different diagnostic and treatment programs. Despite these improvements, the presence of metastasis, disease recurrence, and advanced local tumors continue to remain poor prognostic factors. Median survival without treatment is <8 months from the moment of its presentation, and a survival rate at 5 years of 11% is the best prognosis for those who present with local metastasis. Even in patients with limited metastatic disease, 5-year survival is exceptional. Patients with hepatic metastasis of colorectal cancer have a median survival of 5 to 20 months with no treatment. Approximately 20 to 30% of patients with colorectal metastasis have disease confined to the liver, and this can be managed with surgery. Modern surgical strategies at the main hepatobiliary centers have proved that hepatectomy of 70% of the liver can be performed, with a mortality rate of <5%. It is very important to have knowledge of predisposing factors, diagnostic methods, and treatment of hepatic metastasis. However, the establishment of newer, efficient, preventive screening programs for early diagnosis and adequate treatment is vital. How to cite this article: Valderrama-Treviño AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic Metastasis from Colorectal Cancer. Euroasian J Hepato-Gastroenterol 2017;7(2):166-175.
Keywords: Hepatic metastasis; Treatment of metastasis.; Colorectal cancer.
Conflict of interest statement
Source of support: Alan Isaac Valderrama-Trevino is a doctoral student from Programa de Doctorado en Ciencias Biomedicas, Universidad Nacional Autonoma de México (UNAM) and received fellowship 694871 from CONACYT. Conflict of interest: None
Figures
Similar articles
-
Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions.Dis Colon Rectum. 2003 Oct;46(10 Suppl):S22-31. doi: 10.1097/01.DCR.0000089106.71914.00. Dis Colon Rectum. 2003. PMID: 14530655 Clinical Trial.
-
Clinical relevance of oncologic prognostic factors in the decision-making of pre-hepatectomy chemotherapy for colorectal cancer hepatic metastasis: the priority of hepatectomy.World J Surg Oncol. 2018 Feb 7;16(1):24. doi: 10.1186/s12957-018-1322-9. World J Surg Oncol. 2018. PMID: 29415722 Free PMC article.
-
[Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].Chir Ital. 2005 Sep-Oct;57(5):555-70. Chir Ital. 2005. PMID: 16241086 Italian.
-
Current management of colorectal hepatic metastasis.Expert Rev Gastroenterol Hepatol. 2009 Apr;3(2):131-44. doi: 10.1586/egh.09.8. Expert Rev Gastroenterol Hepatol. 2009. PMID: 19351284 Review.
-
Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article-.J Med Life. 2015;8 Spec Issue(Spec Issue):12-4. J Med Life. 2015. PMID: 26361505 Free PMC article. Review.
Cited by
-
CXCL1 Regulated by miR-302e Is Involved in Cell Viability and Motility of Colorectal Cancer via Inhibiting JAK-STAT Signaling Pathway.Front Oncol. 2021 May 17;10:577229. doi: 10.3389/fonc.2020.577229. eCollection 2020. Front Oncol. 2021. PMID: 34079750 Free PMC article.
-
Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity.BMC Chem. 2022 Nov 1;16(1):81. doi: 10.1186/s13065-022-00873-3. BMC Chem. 2022. PMID: 36320042 Free PMC article.
-
Comparative efficacy and adverse reactions of apatinib-chemotherapy combinations versus chemotherapy alone for treatment of advanced colorectal cancer: a meta-analysis of randomized controlled trials.Am J Transl Res. 2022 Sep 15;14(9):6703-6711. eCollection 2022. Am J Transl Res. 2022. PMID: 36247297 Free PMC article.
-
Genome-Wide Scan for Copy Number Alteration Association with Relapse-Free Survival in Colorectal Cancer with Liver Metastasis Patients.J Clin Med. 2018 Nov 18;7(11):446. doi: 10.3390/jcm7110446. J Clin Med. 2018. PMID: 30453668 Free PMC article.
-
Let-7i-3p inhibits the cell cycle, proliferation, invasion, and migration of colorectal cancer cells via downregulating CCND1.Open Med (Wars). 2022 Jun 7;17(1):1019-1030. doi: 10.1515/med-2022-0499. eCollection 2022. Open Med (Wars). 2022. PMID: 35795002 Free PMC article.
References
-
- Adam R, de Gramont A, Figueras J, Kokudo N, Kunstilnger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015 Nov;41(9):729–741. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources